Corium International Inc. (NASDAQ:CORI) shares saw unusually-strong trading volume on Friday . Approximately 80,982 shares were traded during trading, an increase of 23% from the previous session’s volume of 65,978 shares.The stock last traded at $6.25 and had previously closed at $6.85.

A number of analysts have commented on CORI shares. FBR & Co reaffirmed a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Leerink Swann reaffirmed a “buy” rating and set a $14.00 price target on shares of Corium International in a research report on Wednesday, May 18th. Jefferies Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Corium International in a research report on Wednesday, May 11th. Zacks Investment Research raised Corium International from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Tuesday, July 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Corium International in a research report on Thursday, June 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Corium International presently has an average rating of “Buy” and an average target price of $11.92.

The company’s market capitalization is $138.40 million. The stock’s 50-day moving average is $4.67 and its 200 day moving average is $4.37.

Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Equities analysts expect that Corium International Inc. will post ($1.63) earnings per share for the current year.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.